Caprihans India Limited announced its Q3FY26 financial results through a board meeting outcome dated February 10, 2026, reporting continued losses amid challenging market conditions. The pharma packaging solutions company posted a net loss of ₹15.96 crores, showing improvement from the ₹18.51 crores loss recorded in the corresponding quarter of the previous year.

Financial Performance Overview

The company's standalone financial results revealed mixed performance indicators for Q3FY26. While the net loss narrowed compared to the previous year, revenue from operations declined significantly.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Caprihans India showed improved performance compared to the previous year. The company reported a net loss of ₹54.48 crores against ₹64.50 crores in the corresponding period of FY25.

Consolidated Financial Performance

The consolidated results, which include subsidiary Bilcare Research GmbH, showed similar trends with a net loss of ₹15.60 crores for Q3FY26 compared to ₹18.56 crores in the previous year.

Corporate Restructuring and Leadership Changes

The company's Board of Directors approved several significant corporate actions during their meeting held on February 10, 2026. The most notable decision involved the redemption of 2,80,50,000 preference shares valued at ₹28.05 crores, reducing the total outstanding preference shares from 16,66,50,000 to 13,86,00,000 shares.

In terms of leadership transitions, Mr. Guman Mal Jain resigned from his position as Chief Financial Officer effective February 10, 2026, citing personal reasons. The Board appointed Mr. Pritam Paul as the new CFO effective February 11, 2026, in addition to his existing role as Business Head – Flexible PVC.

Board Composition Enhancement

The company strengthened its board composition with the appointment of Mr. Sanjeev D. Tole as Additional Independent Director effective February 10, 2026. Mr. Tole brings over 50 years of experience in corporate governance, Company Law, and regulatory compliances, having served in senior positions across various organizations.

Exceptional Items Impact

The company recorded exceptional expenses of ₹1.72 crores in Q3FY26, primarily related to the impact of new Labour Codes notified by the Government of India in November 2025. These codes consolidated 29 existing labour laws and resulted in incremental gratuity provisions due to changes in wage definitions.

Operational Highlights

Caprihans India continues to focus on its core business of pharma packaging solutions, operating as a single reportable segment. The company maintains its registered office at Shiroli, Rajgurunagar, Pune, and operates with a paid-up equity share capital of ₹14.62 crores as of December 31, 2025. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors providing their limited review report on the unaudited financial statements.